Open AccessDoes prostate specific antigen act as predictor in benign prostatic hyperplasia?
Author(s) -
Ankur Gopendra Das,
Amol Langade
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns2.5105
Subject(s) - medicine , urology , rectal examination , hyperplasia , lower urinary tract symptoms , prostate specific antigen , international prostate symptom score , prostate , creatinine , transrectal ultrasonography , urinary system , cancer
Background: Benign prostatic hyperplasia (BPH) is associated with increase in prostate volume (PV) and increased epithelial production of prostate specific antigen (PSA). Both, PV and serum PSA, offers a non-invasive guide for identifying patients at high-risk of disease progression and making treatment decisions. Objective: To evaluate the serum PSA concentration and PV in cases of lower urinary tract symptoms (LUTS) secondary to BHP. Methods: Two hundred eligible symptomatic BHP patients with LUTS, were recruited into the study. All relevant history, clinical findings, International Prostate Symptom Score (IPSS) category and digital rectal examination grading were recorded. Blood levels of PSA, blood urea and serum creatinine were estimated followed by abdominal and trans-rectal ultrasonography (USG) to assess the size of prostate, PV, the lobes involved and residual urine volume. The results were compiled and analyzed using statistical software R version 3.6.3. Results: The mean age of the BHP patients was 68.22 ± 9.18 years, with 36% suffering from acute urinary retention (AUR). The mean IPSS, PV and PSA levels were 23.80 ± 5.67, 58.40 ± 18.56 cc and 4.61 ± 1.66 ng/mL, respectively. The mean blood urea and serum creatinine levels were 32.02 ± 6.05 mg/dL and 1.10 ± 0.28 mg/dL, respectively.